Abstracts tagged "interleukins (IL)"

Abstract Number: 1447 • 2016 ACR/ARHP Annual Meeting
Therapeutic Blockade of Interleukin-6 Trans-Signalling Restores Vascular Function in Murine Collagen Induced Arthritis
Ruth Davies¹, Jessica O Williams², Katie Sime², Ellyn Hughes², Lauren A. Jordan², Charlotte Rawlings², Derek Lang³, Stefan Rose-John⁴, Simon A. Jones⁵, Anwen S. Williams² and Ernest H. Choy^6,7, ¹CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ²Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Institute of Biochemistry, Christian Albrechts University, Kiel, Germany, ⁵Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Cardiff, Wales, ⁶Section of Rheumatology, Cardiff University, Cardiff, Great Britain, ⁷CREATE Center, Division of Infection and Immunity,, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA), mainly due to cardiovascular disease (CVD). While molecular mechanisms underlining this clinical observation are unknown, systemic elevations…
Abstract Number: 1569 • 2016 ACR/ARHP Annual Meeting
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis
Masako Tsukamoto¹, Noriyuki Seta², Keiko Yoshimoto¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Internal Medicine, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan
Background/Purpose: The study enrolled 35 untreated RA patients and 14 healthy volunteers. DAS28-ESR was evaluated and peripheral blood samples were obtained at baseline and following…
Abstract Number: 2460 • 2015 ACR/ARHP Annual Meeting
B10 Cells May be Involved in Controlling Disease Activity in Polyarticular Juvenile Idiopathic Arthritis Patients
Qianzi Zhao¹ and Lawrence K. Jung², ¹Rheumatology, Children's National Medical Center, Washington, DC, ²Pediatric Rheumatology, Children's National Medical Center, Washington, DC
Background/Purpose: In addition to antibodies production, B cells have been shown to have down-regulatory function on immune response in both mouse and human. The down-regulatory…
Abstract Number: 2848 • 2015 ACR/ARHP Annual Meeting
Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis
Vibeke Strand¹, M. Elaine Husni², William Reichmann³, Keith Betts⁴, Jenny Griffith⁵, Yan Song³, Marci Beppu⁶ and Arijit Ganguli⁵, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, ³Analysis Group Inc., Boston, MA, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie, Newcastle, WA
Background/Purpose: Multiple disease-modifying therapies for treatment of psoriatic arthritis (PsA) are available. However, there are limited data directly comparing these biologic therapies and the recently…
Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Alice B. Gottlieb¹, Diamant Thaci², Andrew Blauvelt³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ²Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
Abstract Number: 2883 • 2015 ACR/ARHP Annual Meeting
Relationship Between Improvements in Fatigue and Signs & Symptoms of Active Psoriatic: Arthritis a Sub-Analysis of a Phase 3 Study with Secukinumab
Laure Gossec¹, Tore K. Kvien², Philip G. Conaghan³, Mikkel Østergaard⁴, Juan D. Cañete⁵, C. Gaillez⁶, Shephard Mpofu⁶, Bintu Sherif⁷ and Steffen Jugl⁸, ¹Rheumatology Department, Paris 06 University,Hôpital Pitié Salpêtrière, Paris, France, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Durham, NC, ⁸BF I&D GPA, Health Economics and Outcomes Research, Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Fatigue is highly important to patients (pts) with psoriatic arthritis (PsA). Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved the signs and symptoms of active…
Abstract Number: 2887 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
Atul A. Deodhar¹, Dominique Baeten², Joachim Sieper³, Brian Porter⁴, Albert Widmer⁵ and Hanno Richards⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³University Clinic Benjamin Franklin, Berlin, Germany, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in 2 Phase 3, randomized, double-blind, placebo (PBO)-controlled studies, MEASURE…
Abstract Number: 200 • 2015 ACR/ARHP Annual Meeting
Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10
Vineesh Raveendran¹, Jason Springer², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan¹, ¹Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis. Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression…
Abstract Number: 3039 • 2015 ACR/ARHP Annual Meeting
Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease
Toshikatsu Kaburaki¹, Shinji Harihara², Rie Tanaka³, Hiromasa Sawamura⁴, Ai Nishi⁴, Atsushi Hatamochi⁵, Jun Shimizu⁶, Masumi Takeuchi⁷, Shoji Kuwata⁸, Hidetoshi Kawashima⁹ and Fujio Takeuchi¹⁰, ¹Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, ³Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, ⁴Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁵Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, ⁶Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁷Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, ⁸Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, ⁹Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, ¹⁰Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Behçet's disease (BD) is known to be associated with HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07, IL-10 and IL23R-IL12RB polymorphisms…
Abstract Number: 593 • 2015 ACR/ARHP Annual Meeting
Predicting the Need for Additional Treatment in Early Rheumatoid Arthritis Patients Treated to Target on Methotrexate Monotherapy
Xavier Teitsma¹, Johannes Jacobs², Paco Welsing³, Thasia Woodworth⁴, Attila Pethö-Schramm⁵, Michelle Borm⁶, Corrado Bernasconi⁵, Floris Lafeber¹ and Johannes W J Bijlsma⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Department Rheumatology and clinical immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, Los Angeles, CA, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁷Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Joint damage and functional disability can be reduced by intensive treatment of newly diagnosed rheumatoid arthritis (RA) patients during the "window of opportunity". Although…
Abstract Number: 3221 • 2015 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Yunbo Wei³, Xiaolin Sun⁴, Jianping Guo⁵, Yuebo JIn⁶, Rulin Jia⁶, Lei Zhu⁶, Zhaohua Hou⁷, Yaping Chen⁸, Yuan An⁶, Yuan Jia⁶, Xu Liu⁶, Limin Ren⁶, Ru Li⁶, HUA YE⁹, Shi Chen⁶, Xuewu Zhang¹⁰, Yin Su¹¹, Eric Morand¹², Yu Di¹³ and Zhanguo Li⁶, ¹Peking Univerisity People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁴People's hospital,Peking University, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Peking University People's Hospital, Beijing, China, ⁷Shandong Analysis and Test Center, Beijing, China, ⁸Monash University, Clayton, Austria, ⁹No.11 XIZHIMENG SOUTH STREET,, Peking University People's Hospital, Beijing, China, ¹⁰Rheumatology, Peking University People's Hospital, Beijing, China, ¹¹Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ¹²Medicine, Monash University, Clayton, Australia, ¹³Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-system involvement, associated with an imbalance between effector and regulatory CD4+ T cells. The…
Abstract Number: 967 • 2015 ACR/ARHP Annual Meeting
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis
Roy Fleischmann¹, Frank Wagner², Alan J. Kivitz³, Heikki T. Mansikka⁴, Nasser Khan⁴, Jia Liu⁴, Jacob Gagnon⁴, Feng Hong⁵, Melanie Ruzek⁴ and Robert J. Padley⁴, ¹University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ²Charité Research Organisation GmbH, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Worcester, MA
Background/Purpose: TNF and IL-17 independently contribute to the pathophysiology of rheumatoid arthritis (RA) acting synergistically to induce mediators of inflammation and joint destruction. Selective dual…
Abstract Number: 977 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Active- and Placebo-Controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naïve to Biologic Disease Modifying Anti-Rheumatic Drugs with Active Psoriatic Arthritis
Philip J. Mease¹, Désirée van der Heijde², Christopher T. Ritchlin³, Raquel Cuchacovich^4,5, Catherine L. Shuler⁵, Chin H. Lee⁵, Suvajit Samanta⁵, Chen-Yen Lin⁵, Dafna D. Gladman⁶ and Harald Vangerow⁵, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ³Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁴School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis which includes peripheral arthritis, enthesitis, dactylitis, and spondylitis manifestations. Ixekizumab, under investigation…
Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Charlotte Hua¹, Rachel Audo², Nataliya Yeremenko³, Dominique Baeten⁴, Michael Hahne², Bernard Combe⁵, Jacques Morel⁵ and Claire I. Daien⁵, ¹Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²IGMM-CNRS UMR5535, Montpellier, France, ³Academic medical center, University of Amsterdam, Amsterdam, France, ⁴1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…
Abstract Number: 1156 • 2015 ACR/ARHP Annual Meeting
Th17 Cytokines Regulate Osteoclastogenesis in Rheumatoid Arthritis
MIN-YOUNG JUNG¹, Hae-Rim Kim², HYUN-SOOK KIM³, HO-YOUN KIM¹ and Sang Heon Lee⁴, ¹Konkuk university hospital, Seoul, South Korea, ²Division of Rheumatology, Konkuk University School of Medicine, Seoul, South Korea, ³Soonchenhyang university school of medicine, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea
Background/Purpose: This study aimed to determine the regulatory effect of Th17 cytokines on osteoclastogenesis in rheumatoid arthritis (RA). Methods: The expression of interleukin (IL)-17 and…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].